The companies may be comfortable with the PBAC considering their medicines, but the committee can not just do whatever it likes. If companies are not comfortable, they have all the legal power to stop the committee by invoking the legal protections they have over their proprietary information. …
Companies have all the power in this process, if they choose to use it
July 21, 2025 Latest NewsBioPharmaNews of the DayComment
Latest Video
New Stories
-
PYC to present early polycystic kidney disease trial data at US nephrology conference
October 7, 2026 - - Australian Biotech -
CSL raises US$1.5 billion from US bond investors to refinance debt
October 7, 2026 - - Latest News -
Every serious attempt to reform PBS pricing has run into the same problem
October 7, 2026 - - Latest News -
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 - - Latest News -
The patient who knows what they want is informed and not a danger
October 7, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News